The latest usage guide of Bituvit, indications, usage and dosage, etc.

Indications

It is indicated for the treatment of HIV-1infected adult patients, as well as pediatric patients weighing at least 14kg, especially those who have not yet received antiretroviral therapy.

For patients who have achieved virological suppression on stable antiretroviral therapy (i.e., HIV-1 RNA levels are less than 50 copies/ml), and who have no history of treatment failure and no resistance to the components of this product, Bituvir can be an ideal alternative to existing treatment options.

Mechanism of action

The reason why Bituvi can play a significant role in anti-HIV-1 treatment is due to its unique drug composition and antiviral method. It combines the innovative agonist-free integrase inhibitor bictegravir, containing 50 mg of bictegravir, 200 mg of emtricitabine, and 25 mg of tenofovir alafenamide per tablet. These three ingredients work synergistically to effectively and quickly inhibit the replication of the HIV virus. In particular, bictegravir has a low risk of drug resistance and a very high genetic barrier, so you don’t have to worry too much about the development of drug resistance if you occasionally miss a dose.

Medication method

Dosing Bituvail varies based on the patient's weight and specific situation. For adult and pediatric patients weighing at least 25kg or receiving long-term hemodialysis with an estimated creatinine clearance less than 15 mL/minThe recommended dose for adults is one tablet per day (bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg), which can be taken with or without food. This dose is also recommended for pregnant individuals who have achieved virological suppression. For pediatric patients weighing more than 14kg and less than 25kg, the usual dose is one tablet per day (bictegravir30mg/emtricitabine120mg/tenofovir alafenamide 15mg), also taken with or without food.

side effects

Although Bituvi is effective in treatingHIV-1 infection, there may be some side effects. Common side effects include gastrointestinal reactions (such as nausea, diarrhea, vomiting, etc.), neurological symptoms (such as headache, dizziness, etc.), psychiatric symptoms (such as depression, anxiety, etc.), skin symptoms (such as rash, itching, etc.), and other uncommon side effects (such as anemia, joint pain, fatigue, etc.). More rarely, some patients may experience serious side effects, such as behavioral or sleep disturbances.

Warnings and precautions

Before using BITOVIR, patients need to pay attention to the following matters: it is prohibited for those allergic to BITOVIR; pregnant and lactating women should use it with caution and consult a doctor; 18 The safety and efficacy of the drug in children under the age of 18 are uncertain; BITOVIB is prohibited from being used together with rifampicin and drugs to treat hepatitis B virus.

drug interactions

Bitavi may interact with certain drugs, such as anti-tuberculosis drugs (such as rifampicin), anti-epileptic drugs (such as oxcarbazepine), immunosuppressants (such as cyclosporine), and other antiviral drugs (such as drugs containing emtricitabine, tenofovir disoproxil fumarate, etc.). In addition, carbonic anhydrase inhibitors (such as omeprazole) and antacids (such as sucralfate) may also affect the absorption and efficacy of Bituvir.

Medication for special populations

For special groups such as pregnant and lactating women and those with hepatic insufficiency, caution is required and consultation with a doctor is required when using BITOVIL. The doctor will develop an appropriate medication plan based on the patient's specific condition to ensure the safety and effectiveness of the treatment.